Is there a role for inhaled nitric oxide as a rescue therapy in respiratory failure associated with hematologic malignancies?

Mark T. Keegan, Eric Nygren, Bekele Afessa, William Hogan, Barry A. Harrison

Research output: Contribution to journalArticle

Abstract

Inhaled nitric oxide has been demonstrated to improve oxygenation in critically ill patients requiring mechanical ventilation. We therefore performed a retrospective review to determine the outcome of patients with hematological malignancies and acute respiratory failure who received inhaled nitric oxide (INO) in a multidisciplinary intensive care unit of a single tertiary referral medical center. Thirteen patients with hematological malignancies who required endotracheal intubation and mechanical ventilation and received INO for acute respiratory failure between January 1998 and December 2002 were identified. Mean ± standard deviation (SD) age was 47.6 (±13.2) years. The mean ± SD Acute Physiology and Chronic Health Evaluation (APACHE) III score on the day of ICU admission was 94.1 ± 33.7 with a mean (SD) predicted probability of ICU death of 42.4% (±28.6). Mean APACHE III score on the day of initiating INO was 107.6 (±34.4) with a predicted mortality in the intensive care unit of 72.7% (±23.3). Mean PaO2 to FiO 2 (PF) ratios (±SD) prior to, and immediately after, the initiation of INO were 62.6 (±28.2) and 111 (±65.1), respectively (P < 0.001). The median duration of INO therapy was 41.8 h (interquartile range, 6.3-98.2). Patients with hematological malignancies and acute respiratory failure to whom INO was administered had clinical deterioration since ICU admission. Despite a marked initial improvement in arterial oxygen tension, all patients ultimately died in the intensive care unit, 8 of them within 48 h of initiating INO. Therefore, despite initial improvement in oxygenation, we did not observe any survival benefit to INO in this setting.

Original languageEnglish (US)
Pages (from-to)729-734
Number of pages6
JournalAmerican Journal of Hematology
Volume81
Issue number10
DOIs
StatePublished - Oct 2006

Fingerprint

Hematologic Neoplasms
Respiratory Insufficiency
Nitric Oxide
Intensive Care Units
APACHE
Therapeutics
Artificial Respiration
Intratracheal Intubation
Tertiary Care Centers
Critical Illness
Arterial Pressure
Oxygen
Survival
Mortality

Keywords

  • Acute respiratory failure
  • Hematological malignancy
  • Inhaled nitric oxide
  • Intensive care unit
  • Outcome

ASJC Scopus subject areas

  • Hematology

Cite this

Is there a role for inhaled nitric oxide as a rescue therapy in respiratory failure associated with hematologic malignancies? / Keegan, Mark T.; Nygren, Eric; Afessa, Bekele; Hogan, William; Harrison, Barry A.

In: American Journal of Hematology, Vol. 81, No. 10, 10.2006, p. 729-734.

Research output: Contribution to journalArticle

Keegan, Mark T. ; Nygren, Eric ; Afessa, Bekele ; Hogan, William ; Harrison, Barry A. / Is there a role for inhaled nitric oxide as a rescue therapy in respiratory failure associated with hematologic malignancies?. In: American Journal of Hematology. 2006 ; Vol. 81, No. 10. pp. 729-734.
@article{dff9e60c82d741c3bb81ae11420efe3e,
title = "Is there a role for inhaled nitric oxide as a rescue therapy in respiratory failure associated with hematologic malignancies?",
abstract = "Inhaled nitric oxide has been demonstrated to improve oxygenation in critically ill patients requiring mechanical ventilation. We therefore performed a retrospective review to determine the outcome of patients with hematological malignancies and acute respiratory failure who received inhaled nitric oxide (INO) in a multidisciplinary intensive care unit of a single tertiary referral medical center. Thirteen patients with hematological malignancies who required endotracheal intubation and mechanical ventilation and received INO for acute respiratory failure between January 1998 and December 2002 were identified. Mean ± standard deviation (SD) age was 47.6 (±13.2) years. The mean ± SD Acute Physiology and Chronic Health Evaluation (APACHE) III score on the day of ICU admission was 94.1 ± 33.7 with a mean (SD) predicted probability of ICU death of 42.4{\%} (±28.6). Mean APACHE III score on the day of initiating INO was 107.6 (±34.4) with a predicted mortality in the intensive care unit of 72.7{\%} (±23.3). Mean PaO2 to FiO 2 (PF) ratios (±SD) prior to, and immediately after, the initiation of INO were 62.6 (±28.2) and 111 (±65.1), respectively (P < 0.001). The median duration of INO therapy was 41.8 h (interquartile range, 6.3-98.2). Patients with hematological malignancies and acute respiratory failure to whom INO was administered had clinical deterioration since ICU admission. Despite a marked initial improvement in arterial oxygen tension, all patients ultimately died in the intensive care unit, 8 of them within 48 h of initiating INO. Therefore, despite initial improvement in oxygenation, we did not observe any survival benefit to INO in this setting.",
keywords = "Acute respiratory failure, Hematological malignancy, Inhaled nitric oxide, Intensive care unit, Outcome",
author = "Keegan, {Mark T.} and Eric Nygren and Bekele Afessa and William Hogan and Harrison, {Barry A.}",
year = "2006",
month = "10",
doi = "10.1002/ajh.20695",
language = "English (US)",
volume = "81",
pages = "729--734",
journal = "American Journal of Hematology",
issn = "0361-8609",
publisher = "Wiley-Liss Inc.",
number = "10",

}

TY - JOUR

T1 - Is there a role for inhaled nitric oxide as a rescue therapy in respiratory failure associated with hematologic malignancies?

AU - Keegan, Mark T.

AU - Nygren, Eric

AU - Afessa, Bekele

AU - Hogan, William

AU - Harrison, Barry A.

PY - 2006/10

Y1 - 2006/10

N2 - Inhaled nitric oxide has been demonstrated to improve oxygenation in critically ill patients requiring mechanical ventilation. We therefore performed a retrospective review to determine the outcome of patients with hematological malignancies and acute respiratory failure who received inhaled nitric oxide (INO) in a multidisciplinary intensive care unit of a single tertiary referral medical center. Thirteen patients with hematological malignancies who required endotracheal intubation and mechanical ventilation and received INO for acute respiratory failure between January 1998 and December 2002 were identified. Mean ± standard deviation (SD) age was 47.6 (±13.2) years. The mean ± SD Acute Physiology and Chronic Health Evaluation (APACHE) III score on the day of ICU admission was 94.1 ± 33.7 with a mean (SD) predicted probability of ICU death of 42.4% (±28.6). Mean APACHE III score on the day of initiating INO was 107.6 (±34.4) with a predicted mortality in the intensive care unit of 72.7% (±23.3). Mean PaO2 to FiO 2 (PF) ratios (±SD) prior to, and immediately after, the initiation of INO were 62.6 (±28.2) and 111 (±65.1), respectively (P < 0.001). The median duration of INO therapy was 41.8 h (interquartile range, 6.3-98.2). Patients with hematological malignancies and acute respiratory failure to whom INO was administered had clinical deterioration since ICU admission. Despite a marked initial improvement in arterial oxygen tension, all patients ultimately died in the intensive care unit, 8 of them within 48 h of initiating INO. Therefore, despite initial improvement in oxygenation, we did not observe any survival benefit to INO in this setting.

AB - Inhaled nitric oxide has been demonstrated to improve oxygenation in critically ill patients requiring mechanical ventilation. We therefore performed a retrospective review to determine the outcome of patients with hematological malignancies and acute respiratory failure who received inhaled nitric oxide (INO) in a multidisciplinary intensive care unit of a single tertiary referral medical center. Thirteen patients with hematological malignancies who required endotracheal intubation and mechanical ventilation and received INO for acute respiratory failure between January 1998 and December 2002 were identified. Mean ± standard deviation (SD) age was 47.6 (±13.2) years. The mean ± SD Acute Physiology and Chronic Health Evaluation (APACHE) III score on the day of ICU admission was 94.1 ± 33.7 with a mean (SD) predicted probability of ICU death of 42.4% (±28.6). Mean APACHE III score on the day of initiating INO was 107.6 (±34.4) with a predicted mortality in the intensive care unit of 72.7% (±23.3). Mean PaO2 to FiO 2 (PF) ratios (±SD) prior to, and immediately after, the initiation of INO were 62.6 (±28.2) and 111 (±65.1), respectively (P < 0.001). The median duration of INO therapy was 41.8 h (interquartile range, 6.3-98.2). Patients with hematological malignancies and acute respiratory failure to whom INO was administered had clinical deterioration since ICU admission. Despite a marked initial improvement in arterial oxygen tension, all patients ultimately died in the intensive care unit, 8 of them within 48 h of initiating INO. Therefore, despite initial improvement in oxygenation, we did not observe any survival benefit to INO in this setting.

KW - Acute respiratory failure

KW - Hematological malignancy

KW - Inhaled nitric oxide

KW - Intensive care unit

KW - Outcome

UR - http://www.scopus.com/inward/record.url?scp=33749634288&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33749634288&partnerID=8YFLogxK

U2 - 10.1002/ajh.20695

DO - 10.1002/ajh.20695

M3 - Article

VL - 81

SP - 729

EP - 734

JO - American Journal of Hematology

JF - American Journal of Hematology

SN - 0361-8609

IS - 10

ER -